300204.SZ
300204.SZ
CNE100001237
STAIDSON BIO
Loading chart...

Company Profile

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C powder. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

Related stocks

688062.SS
688062.SS • China
MABWELL (SHANGHAI) BIOSCIENCE C
24.78 CNY
1.66B USD 1Y -47.7%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
301207.SZ
301207.SZ • China
HUALAN VAC
19.88 CNY
1.79B USD 1Y +14.6%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
000403.SZ
000403.SZ • China
PLBIO
9.96 CNY
1.42B USD 1Y -39.1%
002030.SZ
002030.SZ • China
DAJY
6.03 CNY
1.27B USD 1Y -6.1%
688739.SS
688739.SS • China
LIAONING CHENGDA BIOTECHNOLOGY
21.2 CNY
1.32B USD 1Y -21.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
73.8% p.a.
Max Drawdown (5Y)
-80.6%
Sharpe Ratio (5Y)
0.10
Beta Factor
0.48
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (73.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -80.6% in the extended horizon.
ende